The U.S. Food and Drug Administration has granted final approval to Sun Pharmaceutical Industries' abbreviated new drug application for teriflunomide 14mg tablets, therapeutically equivalent to Sanofi's Aubagio, according to regulatory records published Thursday. The approval positions Mumbai-based Sun Pharma — the largest Indian pharmaceutical company by revenue — to enter a US multiple sclerosis drug market estimated at approximately $900 million annually.

Teriflunomide, an oral disease-modifying therapy for relapsing forms of multiple sclerosis, has been marketed by Sanofi as Aubagio since its original FDA approval in 2012. Sun Pharma's generic entry, which met all bioequivalence and manufacturing standards required under the ANDA pathway, is expected to place immediate downward pressure on list prices as pharmacy benefit managers and health insurers evaluate formulary substitution options.

Sun Pharma's regulatory affairs division confirmed that the teriflunomide approval adds to the company's growing central nervous system generic portfolio in the United States, which already includes generic versions of several established neurological therapies. Analysts at brokerage firms tracking Indian pharmaceutical stocks noted that the approval could contribute meaningfully to Sun Pharma's US generics revenue over the next 12 months, particularly given Aubagio's relatively stable patient base and limited biosimilar competition until now.

Sanofi has faced increasing pressure on its legacy multiple sclerosis franchise as newer high-efficacy therapies have shifted prescribing patterns, but Aubagio has retained a significant share of the oral MS treatment segment due to its established safety profile and once-daily dosing convenience. Generic entry by Sun Pharma is expected to accelerate payer-driven switches to lower-cost alternatives, particularly among newly diagnosed patients entering treatment for the first time.

Shares of Sun Pharmaceutical Industries rose modestly in early trading on Indian exchanges following the approval announcement, continuing a broader pattern of positive market reactions to US FDA generic clearances among major Indian drugmakers. The company is expected to begin commercial shipments to US wholesalers within the coming weeks pending supply chain readiness, according to industry observers familiar with the company's manufacturing capacity at its FDA-inspected facilities.